Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Thursday, October 22, 2026

Back to today

Unicycive (UNCY):

Unicycive’s oxylanthanum carbonate NDA earned a March 25, 2027 PDUFA date after two manufacturing-related rejections, with no FDA clinical or safety concerns.

UNCY $110M
Triple S Special Situations Investing 4 clicks

From X

@StableBread 2 clicks

Fajasy on X

Newbury Street II $NTWO, the SPAC taking robot-safety maker FORT Robotics public, closed at $10.81 on October 9, below the cash in its trust. The final proxy for its October 28, 2026 extension vote, filed the same day, shows $186.9M in the trust as of October 7, or $10.833/share. The vote would push Newbury's deadline for closing the deal from November 4 to February 4, 2027, and holders who want to cash out at $10.833 have until 5pm EST on October 26 to submit their shares. The proxy also says the S-4 (the merger filing) is still "to be filed," 52 days after FORT CEO Samuel Reeves told employees to expect it "in the coming weeks." So at $10.81, the market values the FORT deal at zero, and holders who skip this redemption can still cash out at the merger vote, once they've seen the S-4.
@calvinblissett

Calvin Blissett on X

$CNRD: M cap $145m, net cash $28m. $28.83 stock. One of the few specialized ship makers left. Q3 2025 footnotes whow change in severance comp indicating a sale and foudning family estate planning. Sale at 8x 2025 EBITDA yields $54-$55 share price. Won a partnership with Samsung recently. Contract won May 13th is $25m min over next 3 years. Backlog $293m. $3.6 a share in FCF in Q2 2026 alone (stock at $28.83). Founding family involved. Current administration likley to spend more $ on shipbuilding (Fact Sheet: President Donald J. Trump Restores America’s Maritime Dominance – The White House). (Navy shipbuilding stands to get $27 billion in funding in 2026 - Defense One).
@calvinblissett

Calvin Blissett on X

$OPBK: Korean American depositor focus across Southern CA, TX, NV, WA. LTM Owner's Earnings=27.32m 7.8x multiple. 3.7% dividend. At book. 12 full service branches and 1 loan production office (LPO). SBA preferred lender status allows them to unload 75% of loans at a premium. Focused on real estate and housing. 1h 2026 closed 5 LPOS due to "limited market demand" was outside core geography. NPLS +22.7% from YE 2025 to Q2 2026. Cost of deposits end of Q2 2.93%, more than 50% are CDs which is bad as they are not sticky and rate sensitive.
@calvinblissett

Calvin Blissett on X

$FF: $195m EV, 30-40m current EBITDA est at RIN prices. 30m in hidden Arkansas land value (1.7k A out of 2.2k not being used) Thesis: Future Fuel's economics are primarily a bet on biodiesel margins. FF owns a relatively high-cost 59-million-gallon-per-year biodiesel plant, so it generally needs stronger industry margins than larger competitors to justify running at high utilization. The reason a high-cost producer like FF can still matter is the Renewable Fuel Standard (RFS): refiners must satisfy EPA-mandated renewable-fuel volumes, either by blending fuel or acquiring RIN credits. When mandated demand approaches or exceeds economical industry supply, the D4 RIN price rises until the marginal/high-cost producers have enough incentive to restart. FF is one of those marginal producers. That is the core thesis today. D4 RINs have risen sharply from roughly $0.50 in the depressed period to around $1.50, reflecting tighter expected supply/demand, while the EPA's much higher 2026–27 requirements should require substantially more biomass-based diesel production. If the industry remains short of required supply and the RIN bank is drawn down, RINs and therefore biodiesel margins should remain high enough to keep FF operating profitably; roughly speaking, every $0.10/gallon of sustainable margin on ~50 million gallons equals ~$5 million of annual operating profit. A return toward $0.30–$0.50/gallon margins could mean ~$15–25 million of biodiesel operating profit, versus very little or losses when margins collapse. The catalysts are higher plant utilization, continued tight D4 RIN supply/2027 RIN-bank depletion, and stronger chemicals earnings; the major risk is the opposite—RIN prices fall because supply increases, EPA policy weakens demand, exemptions expand, or renewable-diesel capacity overwhelms the market. In simple terms: FF is the expensive factory that the market may now need to run, and the RIN price is effectively what determines whether it gets paid enough to do so.
@calvinblissett 1 click

Calvin Blissett on X

This is a piece by @MagicCompounds $PAL. Quick Glance 4x LTM FCF with synergies coming from March acquisition. PAL consolidated at bottom of cycle (now largest player) and cycle is showing tell-tale signs of rationalization (bankruptcy of 2nd largest player) Positives and Negatives: Highly regarded CEO in the industry who has done this before with high returns (+), getting hurt by diesel (-), should catch up due to mechanism and incentives to continue providing service, current Q may be ugly especially GAAP. Consolidated at bottom of cycle (+). Lots of leverage provides torque and risk (+/-), double the insider sales to purchases (-). 15% market cap buyback with barely any used (-).

Investor Letters

All letters

Carecloud News

CareCloud may attract a private-equity buyer after its Q3 call, with acquiring enough shares the main obstacle to a take-private deal.

CCLD $74M
Calvin Blissett 10 clicks

LXS.DE: a 2028 sale it can force

Lanxess can force Advent to buy at least half its Envalior stake in April 2028, potentially raising about €745 million to reduce net debt.

LPTH $492M
Trade Ideas Flow 21 clicks

Build-A-Bear: A Narrower Path

Build-A-Bear's push into prestuffed toys and broader retail distribution tests brand stretchability, but recent results warrant caution.

BBW $303M
TSOH Investment Research 18 clicks

Twenty Years in the Dark

Tower Properties, $TPRP, went dark after a 2006 squeeze-out cut holders below 300, leaving a Kemper-controlled apartment and office…

TPRP $128M
Orphan REITs 5 clicks

TSOH Weekly Roundup (10/16/2026)

Bumble agreed to a $1.3 billion take-private deal, while Netflix cut about 1,000 jobs and Meta discussed its Muse superintelligence models.

BMBL $783M
TSOH Investment Research 12 clicks
UNCY · long

Unicycive Therapeutics INC

Unicycive Therapeutics fell nearly 50% after a second FDA Complete Response Letter tied to a third-party manufacturer for its primary…

UNCY $110M
Value Investors Club

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 54 of 247

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

90 accounts
Nominate an account

Investor letters we follow

190 firms

Sectors

Ordered by how often our editor reaches for them.